Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 4:55 pm Sale | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | MORGAN STANLEY MS | 1,319,809 1.700% | -2,832,637 (-68.22%) | Filing History |
| 2024-11-04 1:55 pm Purchase | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | VANGUARD GROUP INC | 6,902,150 9.020% | 1,387,007 (+25.15%) | Filing History |
| 2024-10-18 11:59 am Sale | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | STATE STREET CORP STT | 2,736,696 3.600% | -2,615,649 (-48.87%) | Filing History |
| 2024-05-01 4:11 pm Purchase | 2024-04-25 | 13G | Travere Therapeutics, Inc. TVTX | Rock Springs Capital Management LP | 4,411,983 5.790% | 4,411,983 (New Position) | Filing History |
| 2024-02-14 2:35 pm Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 7,384,000 9.830% | 972,000 (+15.16%) | Filing History |
| 2024-02-14 08:58 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Deep Track Capital, LP | 7,522,281 9.990% | 2,940,281 (+64.17%) | Filing History |
| 2024-02-14 06:38 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 4,746,144 6.310% | 1,190,152 (+33.47%) | Filing History |
| 2024-02-13 5:16 pm Purchase | 2023-12-29 | 13G | Travere Therapeutics, Inc. TVTX | VANGUARD GROUP INC | 5,515,143 7.340% | 1,999,697 (+56.88%) | Filing History |
| 2024-02-12 2:58 pm Sale | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | JANUS HENDERSON GROUP PLC JHG | 32,180 0.000% | -5,059,105 (-99.37%) | Filing History |
| 2024-02-09 10:33 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | MORGAN STANLEY MS | 4,152,446 5.500% | 4,152,446 (New Position) | Filing History |
| 2024-02-07 07:37 am Sale | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 500,000 0.670% | -3,918,962 (-88.69%) | Filing History |
| 2024-01-25 09:24 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | STATE STREET CORP STT | 5,352,345 7.120% | 1,128,321 (+26.71%) | Filing History |
| 2024-01-24 09:46 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | BlackRock Inc. BLK | 7,990,020 10.600% | 287,792 (+3.74%) | Filing History |
| 2023-10-06 2:34 pm Purchase | 2023-09-30 | 13G | Travere Therapeutics, Inc. TVTX | BlackRock Inc. BLK | 7,702,228 10.300% | 2,507,443 (+48.27%) | Filing History |
| 2023-05-15 5:02 pm Sale | 2023-05-15 | 13G | Travere Therapeutics, Inc. TVTX | RA Capital Management, L.P. | 0 0.000% | -3,984,681 (Position Closed) | Filing History |
| 2023-03-13 4:30 pm Purchase | 2023-03-01 | 13G | Travere Therapeutics, Inc. TVTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,418,962 5.940% | 1,818,962 (+69.96%) | Filing History |
| 2023-02-14 4:45 pm Sale | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | RA Capital Management, L.P. | 3,984,681 6.200% | -1,629,747 (-29.03%) | Filing History |
| 2023-02-14 3:22 pm Sale | 2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 3,555,992 5.540% | -211,900 (-5.62%) | Filing History |
| 2023-02-14 1:39 pm Purchase | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 6,412,000 9.990% | 2,334,000 (+57.23%) | Filing History |
| 2023-02-14 08:59 am Purchase | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Deep Track Capital, LP | 4,582,000 7.140% | 1,146,800 (+33.38%) | Filing History |